Koray KARAKULAK, Erhan ÖNALAN, Burkay YAKAR, Emir DÖNDER, Faruk KİLİNC, Mehmet Ferit GÜRSU

Polikistik over sendromunda metformin tedavisi alan ve almayanlarda serum asprosin ve trimetilamin oksit düzeyleri

Amaç: Hormonlar ve bağırsak florası ile metabolik hastalıklar arasında potansiyel bir ilişkinin varlığı son zamanlarda dikkat çekmektedir. Asprosin ve trimetilamin oksit (TMAO) düzeyleri metabolik bir hastalık olan polikistik over sendromu (PKOS) ile ilişkili olabilir. Bu çalışmada PKOS'un serum asprosin ve TMAO seviyeleri ile potansiyel ilişkisini araştırmak amaçlanmıştır. Gereç ve Yöntem: Bu kesitsel çalışmaya metformin kullanan 30 PKOS hastası, tedavi almayan 30 PKOS hastası ve 30 sağlıklı kontrol dahil edildi. Katılımcıların demografik, glukoz, insülin direnci, lipid ve hormon profilleri analiz edildi. Serum asprosin ve TMAO düzeyleri ELISA yöntemi ile araştırıldı. Bulgular: PKOS'lu hastalar, kontrollerle karşılaştırıldığında daha yüksek BMI, serum glukozu, trigliserit, ALT, insülin seviyeleri ve HOMA-IR skorlarına sahipti. Serum testosteron düzeyi kontrol grubunda 28,1 ng/dl, metformin tedavisi alan PCOS grubunda 33,3 ng/dl ve tedavi almayan PCOS grubunda 48,0 ng/dl idi ve istatistiksel olarak anlamlı farklılık vardı. Üç grup arasında serum asprosin ve TMAO seviyeleri arasında anlamlı fark yoktu. Sonuç: PKOS'lu bireyler ile sağlıklı kontrollerin serum asprosin ve TMAO seviyeleri arasında anlamlı fark yoktu. Metformin tedavisi ile PKOS hastalarının serum asprosin ve TMAO seviyeleri ile anlamlı bir ilişkisi yoktu.

Anahtar Kelimeler:

Polikistik over sendromu, trimetilamin n-oksit, insülin direnci, gastrointestinal mikrobiyom

Serum asprosin and trimethylamine oxide levels in polycystic over syndrome with and without metformin treatment

Purpose: The presence of a potential relationship between metabolic diseases and hormones and the intestinal flora has recently gained attention. Levels of asprosin and trimethylamine oxide (TMAO) may be associated with polycystic over syndrome (PCOS), which is a metabolic disease. The present study aims to investigate the potential relationship of PCOS with serum asprosin and TMAO levels. Materials and Methods: This cross-sectional study included 30 PCOS patients on metformin, 30 PCOS patients not receiving treatment, and 30 healthy controls. The demographic, glucose, insulin resistance, lipid, and hormone profiles of the participants were analyzed. Serum asprosin and TMAO levels were investigated with the ELISA method. Results: Patients with PCOS had higher BMI, serum glucose, triglyceride, ALT, insulin levels, and HOMA-IR scores compared with controls. The serum testosterone level was 28.1 ng/dl in the control group, 33.3 ng/dl in the PCOS group receiving metformin and 48.0 ng/dl in the untreated PCOS group, and there was a statistically significant difference. Neither serum asprosin nor TMAO levels were significantly different when compared between the three groups. Conclusion: Serum asprosin and TMAO levels of individuals with PCOS and healthy controls were not significantly different. The receipt of metformin treatment by PCOS patients did not have a significant relationship with serum asprosin and TMAO levels.

Keywords:

Polycystic Ovary Syndrome, trimethylamine N-oxide, Insulin Resistance, Gastrointestinal Microbiome,

PDF

___

Kumariya S, Ubba V, Jha RK, Gayen JR. Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective. Autophagy. 2021;17:2706-33.
Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019;17:67.
McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375:54-64.
Moghetti P. Insulin resistance and polycystic ovary syndrome. Curr Pharm Des. 2016;22:5526-34.
Li X, Liao M, Shen R, Zhang L, Hu H, Wu J et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm. 2018;2018:7375294.
Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35:220-3.
Deniz R, Yavuzkir S, Ugur K, Ustebay DU, Baykus Y, Ustebay S et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021;41:279-84.
Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55-71.
Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S et al. Diabetes is associated with higher trimethylamine N-oxide plasma levels. Exp Clin Endocrinol Diabetes. 2016;124:251-56.
Huang J, Liu L, Chen C, Gao Y. PCOS without hyperandrogenism is associated with higher plasma trimethylamine N-oxide levels. BMC Endocr Disord. 2020;20:3.
Annunziata G, Ciampaglia R, Capò X, Guerra F, Sureda A, Tenore GC et al. Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide (TMAO) be a major player? A potential upgrade forward in the DOGMA theory. Biomed Pharmacother. 2021;143:112171.
Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci. 2014;6:104-19.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - PART 2. Endocr Pract. 2015;21:1415-26.
Shang Y, Zhou H, Hu M, Feng H. Effect of diet on insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 2020;105:3346-60.
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566-79.
Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A novel player in metabolic diseases. Front Endocrinol (Lausanne). 2020;11:64.
Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021;20:301-19.
Eyupoglu ND, Caliskan GE, Acikgoz A, Uyanik E, Bjørndal B, Berge RK et al. Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019;91:810-5.